Background {#sec0005}
==========

Aging of somatic tissues and organs comes along with a decline of regenerative capacity. Often, tissue homeostasis, regeneration and repair involve the consecutive emergence and parallel integration of new parenchymal cells, which descend from undifferentiated precursors.

Multipotent stromal progenitor cells also known as [M]{.ul}esenchymal [S]{.ul}tem [C]{.ul}ells (MSC) are pertinent tissue-specific stem cells in adult beings ([Box 1](#tb0005){ref-type="boxed-text"}). The concept of MSC appears to be particularly interesting since this special type of precursor can bring forth a large spectrum of cell types as diverse as bone, cartilage, tendon, or fat precursor cells. Besides these descendants, also terminally differentiated cells that are considered most common and widespread throughout the body, namely interstitial stromal cells and fibroblasts are reckoned direct offspring of MSC, albeit this assumption still lacks good experimental proofs.

MSC reside in a complex three-dimensional network, which comprises a plethora of other cell types such as, in the case of bone marrow, hematopoietic stem cells (HSC), adipocytes, and endothelial cells, altogether embedded in distinct extracellular matrix, and within this blend, MSC guide differentiation of hematopoietic precursor cells into mature progeny \[[@bib0005]\]. MSC appear to exert yet another pertinent function, namely maintaining blood vessel integrity \[[@bib0010; @bib0015]\]. Linked to these presumptions, it can be envisaged that upon tissue damage and injury, MSC are being activated and/or released from their perivascular niche, in order to support wound healing and tissue regeneration.

Also MSC are considered highly effective therapeutic assets to combat a wide spectrum of diseases: most puzzling in this context is that culture-expanded MSC exert immune modulatory activities inasmuch as graft-versus-host disease can be ablated when infusing high MSC numbers in deathly sick patients \[[@bib0020; @bib0025]\]; currently also the potential of *ex vivo* expanded MSC for cell-based therapeutic application in multiple sclerosis patients is being explored \[[@bib0030]\]; and last but not least based on their wide differentiation potential, defined approaches under the premise of regenerative medicine and tissue engineering with the aim of rebuilding damaged or diseased organs and body parts \[[@bib0035]\], has yielded a virtually endless list of only recently initiated clinical trials (see [http://www.trial.gov](http://www.trial.gov/)).

With advancing age, tight control in many aspects of physiology, cell proliferation or signal transduction increasingly deteriorate, and it is reasoned that this ascending deficit may lead to derailed guidance of cell differentiation, which in turn is growing up to adverse effects such as the accumulation of fat deposits in bone and muscles, or impaired healing and fibrosis after severe injury, yet also altered hemopoiesis and autoimmunity.

MSC age {#sec0010}
=======

Similarly to somatic cells, stem cells experience lifelong exposure to various threads such as reactive oxygen species (ROS), biological toxins, harmful chemical agents or physical stressors, which taken together may lead to premature senescence of individual cells, or provokes accelerated cell death, yet also puts cells at risk to cellular transformation \[[@bib0040; @bib0045; @bib0050; @bib0055]\]. In this context, it is also worthwhile to assume that stem cells exhibit enhanced cellular repair capacities, or other still unveiled protective measures, which allow them to efficiently restore otherwise irreparable damages.

While extensive research regarding this particular topic has been undertaken for HSC, and distinct age-related changes and potent molecular mechanisms could be deciphered, distinct details about MSC aging taking place *in vivo* is scarce, simply because we are still lacking consistent knowledge about intrinsic properties in a bodily setting. Conspicuously many characteristic features regarding these stem and progenitor cell types were solely deduced from *in vitro* observations. Hence evaluations of their actual involvement in biological processes of regeneration and repair is currently undertaken, not considering actual activities and interactions that are effectively pursued by MSC in a well choreographed interplay with closely interacting niche cells. More than that such a cellular conglomerate is sure enough further coordinated through powerful factors permeating a jointly shared microenvironment. Also, most of the available literature is specifically focusing on bone marrow-derived MSC, which certainly restrains full comprehensive understanding of their action *in vivo* (see [Box 1](#tb0005){ref-type="boxed-text"}).

A first plain question regarding age-related variations is whether MSC numbers change during adult life span. Synopsis of published work yields conflicting results. This is however largely owned to the problem that there is no agreement on a single standardized protocol for MSC isolation as well as how to proceed with further analysis of primary cell isolates. Another important issue in this context is the often neglected fact that isolates comprise many different cell types, in particular macrophages and various other types of hematopoietic cells, which impact on colony formation *in vitro*. Moreover heterogeneous cultures clearly affect the differentiation potential of single clones, which makes it troublesome to determine the true degree of multipotency of primary MSC. Considering the proliferative potential with age, the published data are less conflicting because most authors report declining performances in long-term culture. This variance could be referred to the fact that MSC show telomere attrition at high passages and this type of genotoxic stress eventually may contribute to the limited replicative life-span *in vitro*. However the length of telomeric ends, although being significantly higher in children \[[@bib0060]\] is maintained at a considerable long length in adult age \[[@bib0065; @bib0070; @bib0075]\]. This suggests that expression of telomerase takes place in MSC *in vivo* be it at a very low constitutive level, or in a transient fashion thereby maintaining the proper structure of chromosome ends. This clearly shows that changes occurring in MSC *in vivo* are only insufficiently described by patchy examinations of MSC, which are replicatively aged in culture.

Assuming a fit cell population can withstand accrued damage and the compounding of irreversible molecular changes longer than aged cells, specification by means of differential expression analysis of those aberrations that take place before a cell slithers into the final state of senescence was expected to yield meaningful insights. Working along this line, CD295 (leptin receptor) was found to increase as a function of intrinsic cellular aging \[[@bib0080]\]. Flow cytometric analysis of this surface marker further discriminated a distinct CD295-bright subpopulation, which interestingly enough also stained positive for annexin V. Conclusively, enhanced CD295 expression marks apoptotic cells. Interestingly, the death rate steadily raises with increasing cellular age. Taken this example into further consideration, it is certainly more valuable to distinguish phenotypic appearances in MSC, which are being isolated from differently aged healthy individuals to unveil those mechanisms, which actually take place in a natural situation instead of solely studying *in vitro* MSC senescence. Indeed, grossevaluations regarding the increased production of ROS \[[@bib0085]\], deviating SOD activity \[[@bib0090]\], whole genome gene expression profiles \[[@bib0070; @bib0075; @bib0095; @bib0100]\], and epigenetic signatures \[[@bib0105]\] have been reported only recently.

Less bone, more fat {#sec0015}
===================

Several functional studies have tackled the question of whether age-associated changes would impinge on MSC properties with respect to their inherent regenerative potential. In an immune suppressed rat model for ischemic cardiomyopathy, human MSC from aged donors performed worse \[[@bib0110]\]. In an attempt to use MSC in cell replacement therapies for neurologic disorders, the neuroectodermal differentiation potential, which can be provoked *in vitro* in MSC derived from young donors, was completely lost in MSC from old donors \[[@bib0115]\]. In several studies addressing the pivotal role of MSC supporting hematopoietic stem cells and their progeny, cells derived from young bone marrow were superior over the aged ones \[[@bib0120; @bib0125]\]. As MSC are clinically applied to suppress graft-versus-host-disease, it would be interesting to uncover whether age-associated changes also skew MSC in this regard. To our knowledge no such attempt has been undertaken yet, nor have experimental results addressing these questions been published to date. Again most data are regarding MSC isolated from bone and bone marrow, and as there are many other sites and cellular populations containing mesenchymal progenitor cells such as the muscle, fat, vessel-associated pericytes, or blood, evidently the aforementioned questions also apply here: as of now, no stringent conclusions can be drawn at this point as most questions in this latter context are still unanswered.

As a consequence of their ubiquitous presence, individual MSC may escape later in life from specific fate control and become diverted to bring forth unwanted progeny. In the case of a vascular mural location, it is conceivable that MSC-like cells may become involved in ectopic calcification of arteries and heart valves, which often occurs in the course of diabetes, renal failure or atherosclerosis \[[@bib0130]\]. Ectopic bone formation is considered a good example for a well established theory in aging biology named antagonistic pleiotropy. Interestingly MSC at pericyte location are undergoing osteogenic differentiation when facing inflammatory conditions \[[@bib0135]\]. These results suggest that MSC within an aged vascular wall show the propensity to develop along the osteogenic lineage rather than turning into cell types that support the vascular architecture.

Contrastingly in osseous tissues at advanced age, both mass and mineral density of cortical and cancellous bone steadily decreases while at the same time more and more fat cells emerge within bone marrow. The actions of crucial determinants of this 'adipogenic switch' are currently being unraveled. The mutual exclusivity of osteoblast and adipocyte cell fates are thought to be determined by factors such as the CCAAT/enhancer binding protein (C/EBP), a trigger for adipogenesis, PPARγ, which promotes adipocyte maturation, or Runx2, an osteoblastic transcriptional mediator. Impaired PPARγ signaling shifts the fate of MSC toward the osteoblast lineage. The wnt pathway can suppress PPARγ, favoring MSC differentiation to osteoblasts. Other transcriptional mediators associated with osteoblast/adipocyte specification include ΔFosB, TAZ, Esr1, Msx2, C/EBPβ, and Id4 \[[@bib0140]\]. The basic leucine-zipper transcription factor, musculo-aponeurotic fibrosarcoma or Maf appears central to osteoblast lineage commitment with age \[[@bib0145]\]. Maf is highly expressed in MSC yet its expression is greatly reduced during aging and in the presence of ROS. This transcriptional modulator is thought to be crucial determinant for skeletal development and for balancing adipogenic versus osteoblastogenic gene expression as *Maf*^+/−^ mice suffer from reduced bone formation while at the same time experience increasing numbers of adipocytes.

Deviations of the age-associated MSC differentiation capacity was reported by many laboratories inasmuch osteogenic potential of MSC isolated from aged donors appears to decline while the respective adipogenic differentiation performance remained unchanged, or worse, was found to be enhanced. Vascular Cell Adhesion Molecule 1 (VCAM1/CD106) was found increased in mesenchymal progenitor cells that are committed to lineage-specific differentiation and this marker is also upregulated in primary MSC derived from bone of aged donors \[[@bib0075]\]. As interferon gamma (IFNγ) or tumor necrosis factor alpha (TNFα) activate VCAM1 expression in MSC, and levels of pro-inflammatory cytokines such as TNFα are increased in older people \[[@bib0150]\], derailed inflammatory cues may scramble the delicate balance of regulatory networks necessary to govern tissue specific regeneration and remodelling ([Figure 1](#fig0005){ref-type="fig"}). In contrast to well adjusted, slightly elevated levels of inflammatory stimuli that are backing up wound and bone healing by supporting osteoblastogenesis \[[@bib0155]\], an inflammatory overshoot, be it acutely or chronically, favors adipogenic differentiation. This is in line with observations that bone loss, also included is the advance of osteoporosis in the course of autoimmune disorders of the bone, is associated if not caused by inflammatory disorders \[[@bib0160; @bib0165]\]. Thus, dominant aberrations within the MSC microenvironment may arise from systemic chronic inflammation, which as mentioned above occurs regularly in elderly persons. It may also be mediated through unbalanced inflammatory and anti-inflammatory networks as a consequence to life-long antigenic burden or age-related diseases. These circumstances are often are often circumscribed by the term '*inflamm*-*aging*' ([Figure 1](#fig0005){ref-type="fig"}).

MSC scent blood {#sec0020}
===============

Hematopoeisis during adulthood takes place in the bone marrow, and one potential HSC niche is congruent with osseous structures, which is the endosteal lining and trabecular cavities of long bones. Osteoblasts were shown to functionally contribute to this confined niche ([Figure 1](#fig0005){ref-type="fig"}). In mouse, nestin-expressing MSC were found to closely associate with HSC and sympathetic nerve fibers \[[@bib0005]\], and the latter regulate HSC mobilization. Comparable to osteoblasts, nestin^+^ MSC condition their microenvironment with high levels of HSC maintenance factors such as the chemokine CXCL12, angiopoietin 1, interleukin 7, or stem cell factor as well as extracellular matrix such as the bone sialo protein, osteopontin ([Figure 1](#fig0005){ref-type="fig"}). Depletion of nestin^+^ cells leads to mobilization of HSC and the homing of transplanted hematopoietic progenitors is greatly reduced. Also treatment with the HSC-mobilizing factor granulocyte colony-stimulating factor stimulates nestin^+^ MSC to produce high amounts of CXCL12 and other factors, which support HSC stemness and niche retention. These data greatly suggest that MSC are indeed functional entities of the endosteal HSC niche. In conclusion, HSC and MSC share a common niche.

Bone marrow also contains adipocytes and it is likely, albeit highly controversial, that they are indeed MSC descendents. Although often perceived as passive space fillers, only recently an inverse correlation between adipocyte numbers and active hematopoiesis became evident. Notably the major inducer of adipogenesis peroxisome proliferator-activated receptor-γ, PPARγ is a negative regulator of osteoblastogenesis, and conceivably also adipocytes can actually form at the expense of osteoblasts \[[@bib0170]\]. In mice, which are genetically incapable of forming adipocytes such as the lipoatrophic A-ZIP/F1 'fatless' mouse strain, or that are treated with the PPARγ inhibitor Bisphenol-A-DiGlycidyl-Ether to induce abrogation of adipogenesis, engraftment of transplanted hematopoietic precursors was greatly enhanced. These findings support the notion that adipocytes exert a suppressive influence within the bone marrow microenvironment through secretion of various factors such as adiponectin or TNFα, each of which can impair hematopoietic proliferation through impeding progenitor activity. At the same time, adipocytes appear to positively influence the most primitive HSC, suggesting that they prevent hematopoietic progenitor expansion while preserving the hematopoietic stem cell pool ([Figure 1](#fig0005){ref-type="fig"}). Conclusively therefore, MSC are the source of two coexisting mature cell types with apparently antagonistic properties on HSCs. Although major questions remain still unanswered, in particular concerning the precise developmental stages that MSCs undergo during differentiation *in situ*, permissive inflammatory influences appear to govern lineage commitment decisions *in vivo*. As a consequence of the dysbalance of osteoblast and adipocyte production, the entire hematopoietic system may become awry.

T lymphocytes and natural killer cells are potential sources of proinflammatory cytokines. MSC interact with T cells and many other immune cells thereby promoting dominant modulatory processes. The effects on CD4 and CD8 T cells are best characterized \[[@bib0175]\]. Independent of whether naïve or antigen-experienced, regardless of their functional state, irrespective of which T-cell receptor expressed, MSC suppress CD4^+^ and CD8^+^ cells non-selectively and non-specifically \[[@bib0180; @bib0185]\]. Of note, IFNγ is required as a crucial 'licensing' step to emit this suppressive activity, and this observation indicates that MSC not only passively withstand inflammatory stimuli, but also actually decisively respond to inflammatory cues. For instance the expression of indoleamine 2,3-dioxygenase (IDO) is upregulated, which in due course leads to tryptophan depletion in lymphocytes resulting in the blockage of their activity and proliferation. Prostaglandin E~2~ (PGE~2~), another mediator with immunosuppressive potential is selectively produced by MSC. It acts in synergy with IDO, and MSC-derived PGE~2~ is capable to reverse an inflammatory environment into an anti-inflammatory one, altering the cytokine secretion profile of dendritic and T-cell subsets \[[@bib0190]\]. Owing to the reversible nature of this inhibition, responding cells are not triggered to undergo apoptosis; it appears likely that MSC to all intents and purposes protect from apoptosis, which is in concordance with the notion that the actual duty of MSC is to support tissue repair.

Toll-like receptors (TLR) are expressed on MSC. TLR4 signaling antagonizes MSC immunosuppressive activity by entailing a proinflammatory profile owing to the secretion of IL-6, IL-8, or TGFβ \[[@bib0195]\]. On the contrary, activation of MSC through TLR3 induces IDO and PGE~2~ as well as the anti-inflammatory cytokine IL-10 \[[@bib0200]\]. Operating along these lines, it was shown that experimental animals suffering from severe sepsis and consequently dying there from, could be rescued through infusion of MSC that reprogrammed macrophages to produce IL10 \[[@bib0205]\] ([Figure 1](#fig0005){ref-type="fig"}). Also the stress-responsive, cytoprotective and immunoregulatory molecule heme oxygenase 1 (HO1) is a key factor in this context. HO1 produced by MSC triggers the formation of specific T regulatory subsets (Tr1 and Th3) and IL-10 production \[[@bib0210]\]. In the presence of MSC also dendritic precursor cells change their fate and acquire regulatory functions by producing IL10 \[[@bib0215]\]. Although the regulatory network governing this particular MSC activity is largely unknown to date, in all likelihood IL10 is pivot.

In conclusion, there are good reasons to believe that fate and function of all aforementioned cell classes are tightly interconnected and age-related changes appear to be compensated to a certain degree by complementary modes, in particular maintaining memory T cells as well as plasma cells in a non-proliferative state, which propagates and supports homeostasis of immunological memory \[[@bib0220]\]. The notion that MSC are functionally plastic has certainly fundamental implications to understand their physiology and their putative role in pathological processes, as well as during aging.
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![Inflammatory ambiences governing MSC polarization, progenitor development and regulatory cues. Mesenchymal stem cells (MSC) nest together with hematopoietic stem cells (HSC) in a common niche comprising specific structural features such as a high density of blood vessels (BV). There, MSC release bioactive molecules into their microenvironment such as the chemokine CXCL12, interleukin 7 (IL7) angiopoietin-1 (ANG1) or bone sialoprotein 1 (BSP1, also called osteopontin). Ambient factors regarding acute or chronic inflammatory insults confound the MSCs' activity to(i)secrete indoleamine 2,3-dioxygenase (IDO), interleukin 6 (IL6), interleukin 8 (IL8), interleukin 10 (IL10), prostaglandin E-2 (PGE~2~), transforming growth factor beta (TGFβ) after activation of toll-like receptors 3 or 4 (TLR3, TLR4) to act on immune cells (IC) to trigger specific T helper (Th) cell responses;(ii)to convey under low or transient inflammatory stimuli the differentiation of osteoblasts (OB) while at the same time checking progression of adipogenic cells (AC); contrastingly within a chronically inflamed periphery, the osteogenic fate of MSC progeny is stalled and adipogenic differentiation upholstered; the latter further propagate an inflammatory milieu through further excretion of tumor necrosis factor alpha (TNFα) or adiponectin;(iii)to support the emergence and diversity of hematopoietic precursor cells (HPC) through strong osseous structures in a protected environment while stem cell proximities destined to degenerate by adipose outgrowth hinder the advent of HPC formation.\
Deteriorating long-lasting chronic inflammation is frequently observed in biological communication systems at advanced age, for which the frequently used expression '*inflamm*-*aging*' has been coined.](gr1){#fig0005}
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